Publications in collaboration with researchers from Hospital Miguel Servet (24)

2024

  1. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

    Annals of Hematology

  2. Role of factor XIII in ischemic stroke: a key molecule promoting thrombus stabilization and resistance to lysis

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 4, pp. 1080-1093

  3. Transcriptomic Analysis of Extracellular Vesicles in the Search for Novel Plasma and Thrombus Biomarkers of Ischemic Stroke Etiologies

    International journal of molecular sciences, Vol. 25, Núm. 8

2023

  1. Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)

    Journal of Clinical Medicine, Vol. 12, Núm. 20

2022

  1. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study

    European Journal of Cancer, Vol. 174, pp. 243-250

  2. SEA 2022 Standards for Global Control of Cardiovascular Risk

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 3, pp. 130-179

2021

  1. Engraftment after autologous hematopoietic stem cell transplantation in patients mobilized with Plerixafor: A retrospective, multicenter study of a large series of patients

    Transfusion and Apheresis Science, Vol. 60, Núm. 3

  2. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

    Leukemia, Vol. 35, Núm. 8, pp. 2358-2370

  3. Treatment of steroid-refractory chronic graft-versus-host disease with imatinib: Real-life experience of the Spanish group of hematopoietic transplantation (GETH)

    Clinical Transplantation, Vol. 35, Núm. 5

2020

  1. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project

    Haematologica, Vol. Online ahead of print

2019

  1. Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

    Cancer Medicine, Vol. 8, Núm. 16, pp. 6955-6966

  2. Standards for global cardiovascular risk management arteriosclerosis

    Clinica e Investigacion en Arteriosclerosis, Vol. 31, pp. 1-43

2017

  1. ¿Es posible la regresión de la placa aterosclerótica?

    Clinica e Investigacion en Arteriosclerosis

2016

  1. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: A longitudinal analysis

    Blood, Vol. 127, Núm. 9, pp. 1151-1162

  2. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 17, Núm. 8, pp. 1127-1136

2015

  1. Foro de debate: Seguridad de las alternativas a la transfusión alogénica en el paciente quirúrgico y/o crítico

    Medicina Intensiva, Vol. 39, Núm. 9, pp. 552-562

2013

  1. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

    New England Journal of Medicine, Vol. 369, Núm. 5, pp. 438-447

  2. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia

    Leukemia, Vol. 27, Núm. 8, pp. 1722-1728

2012

  1. Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: Are they present at diagnosis or are they induced by lenalidomide?

    Haematologica, Vol. 97, Núm. 10, pp. 1608-1611

  2. POEMS syndrome with severe neurological damage clinically recovered with lenalidomide

    Haematologica